| INTRODUC TI ON
Simultaneous with the development of society and the improvement of living standards, coronary heart disease (CHD) has become one of the leading causes of death in the world. Clinical physicians have divided CHD into acute coronary syndrome (ACS) and chronic coronary disease (CAD). The former includes unstable angina pectoris (UA), non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation acute infarction (STEMI). The latter includes stable angina pectoris, asymptomatic myocardial ischemia, and ischemic heart failure. Coronary heart disease is primarily caused by atherosclerosis of coronary arteries. There are many well-established risk factors promoting atherosclerosis, including dyslipidemia, smoking, unhealthy diet, overweight and obesity, hypertension, diabetes mellitus, aging, genetic factors, and family history. [1] [2] [3] Furthermore, it has been recognized that atherosclerosis is primarily an inflammatory disease of the vascular wall. 4 Inflammatory responses are not only involved in the formation of atherosclerotic lesions, but are also associated with complications such as thrombosis and plaque rupture.
Recently, several lines of evidence indicated that inflammation is related to DNA methylation. 5 DNA methylation often occurs in the CpG dinucleotides and tends to be associated with gene transcription silencing. Loss of methylation up-regulates gene expression. 6 Nevertheless, the epigenetic changes are not permanent and are influenced by smoking, 7 hypertension, 8 obesity, and environment.
9-11
Angiopoietin-like protein 2, originating from various cells, has several functions in various chronic inflammatory diseases.
Macrophage-derived ANGPTL2 was reported to accelerate atherosclerosis and CHD development, 12 while endothelial cell-derived ANGPTL2 accelerates vascular inflammation and leads to the development of endothelial dysfunction and atherosclerosis. 12 Circulating ANGPTL2 levels might reflect the severity of atherosclerosis, not lipid metabolic disorders. ANGPTL2 is a proinflammatory mediator and accelerates the development of systemic insulin resistance, endothelial dysfunction, and atherosclerosis in mice. [13] [14] [15] 
| MATERIAL S AND ME THODS

| Participants and clinical data
| Biochemical analyses
Genomic DNA was extracted from peripheral blood samples using the Wizard Genomic DNA Purification kit (Promega, Madison, WI, USA). DNA concentrations were measured by the ultramicro nucleic acid ultraviolet tester (NANODROP 1000, Wilmington, DE, USA).
Plasma levels of TG, TC, HDL, and LDL were measured using an
Our data indicated that in females, promoter DNA hypomethylation of the ANGPTL2 gene is associated with an increased risk of CHD.
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enzymatic end point assay. 19 The ApoA, ApoB, and ApoE levels were measured by the transmission turbidimetric method. 20 The plasma Lp(a) concentrations were determined by a sandwich enzyme-linked immunosorbent assay method [Macra-Lp(a); SDI, Newark, DE, USA]. The concentrations of ALT, AST, ALP, and GGT in plasma were measured by the IFCC reference measurement systems. [21] [22] [23] The ALB level was worked through the bromocresol green method. 24 All the mentioned procedures were followed the standard procedures recommended by the manufacturers. The purified DNA was subjected to bisulfite modification using the EpiTect Bisulfite Kit (Qiagen, Hamburg, Germany) following the manufacturer's protocol. Genomic DNA was chemically modified by sodium bisulfite to convert all unmethylated cytosines to uracils while the methylated cytosines remained unchanged. After bisulfite conversion, polymerase chain reaction (PCR) was used to amplify the target DNA locus.
The primers were designed by PyroMark Assay Design software 2.0 (Qiagen, Hamburg, Germany). The sequences of the PCR primers are listed in Table 1 . The PCR products were measured by pyrosequencing which was conducted by Q96 machine and reagents (PyroMark Q96 ID; Qiagen, Hamburg, Germany). 
TA B L E 1 List of all primers used for PCR
| Statistical analysis
All the statistical analyses were performed using the SPSS package version 18.0 (SPSS Inc, Chicago, IL, USA) and Graph Pad Prism 
| RE SULTS
Clinical and biochemical characteristics of the study population are displayed in Table 2 . There are 122 CHD patients with a mean age of 63.48 ± 10.08 years. The non-CHD participants had a mean age of 59.83 ± 8.94 years. The CHD patients were older than the non-CHD participants. Furthermore, there were more males in the CHD group than in the control group. The number of smokers in the CHD group was greater than those in the non-CHD group. The CHD group had significantly more hypertension than did the control group (P < 0.05).
When we analyzed all the participants according to gender, the mean age for males was 61.73 ± 10.28 years old and mean age for females was 63.22 ± 9.13 years. There was no statistically significant difference in age between the male and female groups. The percentage of smokers was higher in the male group than in the female group (66.7% vs 1.4%, P < 0.001).
There are five CpGs sites in the promoter region (hg, chr9:
127122717-127122850) of the ANGPTL2 gene ( Figure 1 ). According to the DNA sequence of this region, the primers were designed for bisulfite pyrosequencing (Figure 2 ). The methylation levels of the five CpG sites on the ANGPTL2 promoter were measured using the Pyromark Q96 (Qiagen, Hamburg, Germany), and then, we evaluated the methylation levels of the ANGPTL2 gene promoter. Except for the fourth CpG site, the other four CpGs significantly correlated with DNA methylation levels ( Figure 2 , r > 0.8, P < 0.0001). Therefore, these four average methylation levels can be used to indicate the degree of methylation of these four sites. There was no statistical difference between gender for the promoter DNA methylation levels of ANGPTL2 gene ( Table 3, On analysis of the male cases and male controls, the adjusted P value was not statistically significant. Nevertheless, when we conducted a case and control analysis for female, we observed that the adjusted P value reached significance (P = 0.002, Figure 3 ).
It is interesting that we observed a significant association only in the female subgroup ( Figure 3 , females: adjusted P = 0.002; males:
adjusted P = 0.404). However, Figure 3 shows that control groups' data were distributed at both ends of the mean. Then, we divided the control data into two groups: one group was the data above the mean value and the other was the mean value below. We tested the clinical characteristics as we collected (age, gender, smoking, hypertension, blood lipid, hs-CRP, ALB, GLB, ALT, AST, ALP, and GGT), and there were no statistical differences between the two groups. Therefore, we speculate that some factors most likely exist to influence the control data distribution. Comparing of ANGPTL2 gene's CpG4 DNA methylation levels for case and control analysis, there was no significant difference between the groups (P = 0.382). 
| D ISCUSS I ON
Previous studies have shown that global DNA methylation and locus-specific methylation were related with atherosclerosis. 25 High levels of methylation in the promoter region of lipid-related genes,
including ABCA1 and ABCG1, lead to various concentrations of highdensity lipoprotein cholesterol (HDL-C), while HDL-C concentration is associated with CHD. 26, 27 ANGPTL2, a member of the ANGPTL family, promotes chronic inflammation and irreversible pathological tissue remodeling. 14, 28 Studies have shown that ANGPTL2 protein induces a vascular inflammatory response through the integrin 
F I G U R E 3
Comparison of the average DNA methylation levels of ANGPTL2 gene's CpG1-5 between cases and controls α5β1/Rac1/NF-ΚB pathway, leading to atherosclerosis. 29 Studies found that ANGPTL2 was active during various stages of atherosclerosis and promoted leukocyte adhesion to inflamed pre-atherosclerotic and dysfunctional endothelia, in turn contributing to lesion formation. 30 Therefore, our effort to study CHD therapeutic strategies was focused on vascular inflammation that is recognized as a critical pathology driving atherosclerosis progression.
15
At the cardiovascular prevention center of the Montreal Heart Institute, by measuring 33 patients after an ACS and 20 agematched controls, it was found that circulating levels of ANGPTL2
in the ACS group (3.35 ± 0.67 ng/mL) were higher than those in the control group (1.8 ± 0.42 ng/mL). Of the six CpG islands, two
CpG sites (CpG5: cg13662634 and CpG6: 14281592) had methylation differences between the ACS group and the control group.
The degree of CpG5 methylation in the ACS group (34.7% ± 1.4%; P < 0.05, n = 21) was significantly lower than that of the control group (45.8% ± 1.5%, n = 14). When analyzing the younger control group (66.6% ± 0.9%, n = 14), the CpG6 sites in the ACS group showed lower methylation levels (60.4% ± 1.5%, P < 0.05, n = 21);
however, there was no significant difference in the age-matched control group (61.4% ± 2.0%, n = 12). Nevertheless, we found five CpGs sites (from CpG1 to CpG5) of the ANGPTL2 gene promoter region Chr9:127122717-127122850. Our data suggest that four specific methylation sites, CpG1, CpG2, CpG3, and CpG5, are hypomethylated in CHD participants compared to non-CHD cases.
The P25, P50, and P75 values of CHD group were 6.22%, 7.67%, and 10.43%, in contrast to 5.46%, 8.25%, and 17.98% of non-CHD group, respectively, indicating a significant difference between the groups (P = 0.001). Although we selected five CpG sites that were different from Nguyen et al's study, we drew a similar conclusion that CHD participants are hypomethylated in the ANGPTL2 gene promoter region compared with levels in non-CHD participants. Therefore, differential CpG1, CpG2, CpG3, and CpG5 methylation patterns may predict patients at risk of cardiovascular events. In the case-control analysis, the methylation level of ANGPTL2 gene was significantly different in the female group (P = 0.002). Figure 3 shows that, in the female group, methylation levels of the control group were higher than those of the CHD group; however, we could not find a methylation level difference between the case and control subgroups of the male group; therefore, the total case-control differences primarily derive from females. To the best of our knowledge, for the first time, we found that low methylation levels of the ANGPTL2 gene promoter region in the plasma of Han Chinese patients with coronary atherosclerotic heart disease were associated with the risk of CHD. Previous studies demonstrated that the ANGPTL2 gene was highly methylated in ovarian cancer cell lines, where ANGPTL2 was silenced. 31 By contrast, in human osteosarcoma cell lines, the ANGPTL2 gene promoter region was hypomethylated and the expression of ANGPTL2 gene was elevated. 32 Therefore, we drew a conclusion that CHD cases might have much higher circulating ANGPTL2 concentrations than controls. This is in line with the previous studies demonstrating that circulating ANGPTL2 concentration accelerated plaque vulnerability and inflammation. 33, 34 There exist some limitations in our study. The sample size we collected is small. Moreover, we collect the whole peripheral blood which is a mixed population of cells, such as leukocytes, lymphocytes, and other cells. Although the association between methylation level of ANGPTL2 gene and CHD has been clarified, the mechanisms are still not clear.
In conclusion, we have revealed that in females, lower methylation of CpG1, CpG2, CpG3, and CpG5 in the promoter region 
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